Cosmos Health Inc. reported that its Greek distribution arm, Cosmofarm, added nearly 100 new pharmacy customers in 2025, raising its active customer base by roughly 20%. The expansion is expected to generate an additional $40 million in annual revenue as the company expands robotic capacity.
The new customers are driving a 12% increase in annual revenue per customer and a 14% lift in profitability per customer, thanks to higher route density and more efficient order execution. Cosmos Health is investing an additional $1 million in ROWA and A‑frame robotic systems and has added three new delivery routes in Attica to support the projected revenue lift.
While the operational gains are significant, Cosmos Health’s balance sheet shows a total debt of $21.07 million and a debt‑to‑equity ratio of 0.91, accompanied by a negative Altman Z‑Score and negative profit margins. The company’s negative profitability signals that the growth is still being financed against a backdrop of financial strain.
Cosmos Health’s business portfolio extends beyond pharmaceutical distribution to nutraceuticals and telehealth, but the company has not disclosed recent performance data for those segments. The focus on Cosmofarm’s expansion highlights the company’s strategy to strengthen its core distribution network while other segments remain under pressure.
CEO Greg Siokas emphasized that the automation and last‑mile delivery investments will enable the company to capture more volume while maintaining high unit economics. Siokas also noted that insider buying by the CEO has increased, reflecting management’s confidence in the company’s long‑term prospects.
Zacks Small‑Cap Research initiated coverage of Cosmos Health on January 13, 2026, with a price target of $4.50 per share, and the company has received extensions from Nasdaq to meet minimum bid price compliance. These developments suggest that analysts are monitoring the company’s financial health closely as it pursues growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.